Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
detroit blog main
national blog main
national top stories
new york blog main
raleigh-durham blog main
8
×
san diego blog main
san francisco blog main
seattle blog main
texas blog main
8
×
vc
8
×
wisconsin blog main
biotech
boulder/denver blog main
detroit top stories
indiana blog main
life sciences
national
new york top stories
raleigh-durham top stories
san diego top stories
san francisco top stories
seattle top stories
texas top stories
venture capital
wisconsin top stories
boulder/denver top stories
indiana top stories
biogen
celgene
fda
gene editing
ipo
novartis
cancer
gene therapy
medical devices
scott gottlieb
startups
What
bio
roundup
ipo
biogen
healthcare
investors
life
moves
new
science
abbvie’s
activity
allogene
america
approvals
attributes
barbecuing
becker
better
billions
biopharma
boston’s
camping
cancer
capital
car
cardiologist
celgene
center
charm
check
cholesterol
city
clamped
colleagues
conference
continues
convoluted
covid
crispr
Language
unset
Current search:
vc
×
" raleigh-durham blog main "
×
" texas blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
4 years ago
Review: Inside the House of Lies at Theranos
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
In Boston’s Shadow, Rhode Island Fights for Life Science Jobs, Respect